<?xml version='1.0' encoding='utf-8'?>
<document id="18052318"><sentence text="4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists."><entity charOffset="0-48" id="DDI-PubMed.18052318.s1.e0" text="4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines" /><entity charOffset="89-98" id="DDI-PubMed.18052318.s1.e1" text="histamine" /><pair ddi="false" e1="DDI-PubMed.18052318.s1.e0" e2="DDI-PubMed.18052318.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18052318.s1.e0" e2="DDI-PubMed.18052318.s1.e1" /></sentence><sentence text="A series of ketopiperazines were prepared and evaluated for their activity as histamine H 3 antagonists"><entity charOffset="12-27" id="DDI-PubMed.18052318.s2.e0" text="ketopiperazines" /></sentence><sentence text=" From investigation of the tertiary basic center in the aminopropyloxyphenyl template, the 2( R)-methylpyrrolidine was identified as the most potent amine"><entity charOffset="56-85" id="DDI-PubMed.18052318.s3.e0" text="aminopropyloxyphenyl template" /><entity charOffset="91-114" id="DDI-PubMed.18052318.s3.e1" text="2( R)-methylpyrrolidine" /><entity charOffset="149-154" id="DDI-PubMed.18052318.s3.e2" text="amine" /><pair ddi="false" e1="DDI-PubMed.18052318.s3.e0" e2="DDI-PubMed.18052318.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18052318.s3.e0" e2="DDI-PubMed.18052318.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18052318.s3.e0" e2="DDI-PubMed.18052318.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18052318.s3.e1" e2="DDI-PubMed.18052318.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18052318.s3.e1" e2="DDI-PubMed.18052318.s3.e2" /></sentence><sentence text=" In the more rigid piperidineoxyphenyl template the N-cyclobutyl group was the most potent amine"><entity charOffset="19-38" id="DDI-PubMed.18052318.s4.e0" text="piperidineoxyphenyl" /><entity charOffset="52-64" id="DDI-PubMed.18052318.s4.e1" text="N-cyclobutyl" /><entity charOffset="91-96" id="DDI-PubMed.18052318.s4.e2" text="amine" /><pair ddi="false" e1="DDI-PubMed.18052318.s4.e0" e2="DDI-PubMed.18052318.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18052318.s4.e0" e2="DDI-PubMed.18052318.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18052318.s4.e0" e2="DDI-PubMed.18052318.s4.e2" /><pair ddi="false" e1="DDI-PubMed.18052318.s4.e1" e2="DDI-PubMed.18052318.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18052318.s4.e1" e2="DDI-PubMed.18052318.s4.e2" /></sentence><sentence text=" The 4-fluorobenzyol, 4-cyanobenzoyl, and 2,4-difluorobenzoyl groups provided good pharmacokinetic profiles for the various amides"><entity charOffset="5-20" id="DDI-PubMed.18052318.s5.e0" text="4-fluorobenzyol" /><entity charOffset="22-36" id="DDI-PubMed.18052318.s5.e1" text="4-cyanobenzoyl" /><entity charOffset="42-61" id="DDI-PubMed.18052318.s5.e2" text="2,4-difluorobenzoyl" /><entity charOffset="124-130" id="DDI-PubMed.18052318.s5.e3" text="amides" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e0" e2="DDI-PubMed.18052318.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e0" e2="DDI-PubMed.18052318.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e0" e2="DDI-PubMed.18052318.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e0" e2="DDI-PubMed.18052318.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e1" e2="DDI-PubMed.18052318.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e1" e2="DDI-PubMed.18052318.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e1" e2="DDI-PubMed.18052318.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e2" e2="DDI-PubMed.18052318.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18052318.s5.e2" e2="DDI-PubMed.18052318.s5.e3" /></sentence><sentence text=" The PSA and log D values of these compounds suggested low brain penetration" /><sentence text=" The compounds had very high selectivity over other receptors and did not inhibit hepatic cytochrome P450, indicating low drug-drug interaction potential" /><sentence text=" Compound 22i was identified as the best compound of this series based on its overall profile of high potency, selectivity, low brain penetration, lack of CYP450 inhibition, high oral bioavailability, and pharmacokinetic properties" /><sentence text="" /></document>